Glycine supplement for people with fatty liver disease linked to metabolic problems
Tests whether glycine supplements affect liver fat in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease
Key facts
- Where
- Singapore, SingaporeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Source: NCT07285135, who can take part
Where in Singapore
- Singapore General HospitalSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Singapore General Hospital
- Trial code
- NCT07285135
- Record updated
- 27 October 2026
- Original description
This study aims to investigate abnormalities in glycine-dependent metabolic pathways in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether dietary glycine supplementation improves liver health and metabolic function.Read full original descriptionShow less
Investigating the Effects of Dietary Glycine Supplementation in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
This study aims to investigate abnormalities in glycine-dependent metabolic pathways in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether dietary glycine supplementation improves liver health and metabolic function.
The study consists of two components. The first is a cross-sectional case-control study comparing urinary acylglycine concentrations and other glycine-dependent metabolic parameters between 60 participants with MASLD and 30 healthy controls. The second is a randomized, double-blind, placebo-controlled trial in which 60 participants with MASLD will receive either oral glycine supplementation (9 g/day) or placebo for 26 weeks.
The primary outcomes are differences in urinary acylglycine concentrations between participants with MASLD and healthy controls, and changes in hepatic fat content measured by MRI-PDFF and urinary acylglycine concentrations following supplementation. Additional assessments will evaluate amino acid metabolism, glutathione metabolism, oxidative stress, inflammatory responses, and one-carbon metabolism-related biomarkers. Participants will undergo baseline, Week 12, and Week 26 assessments to evaluate metabolic changes and treatment responses.
Inclusion: All subjects:; Age 21-70 years; Ability to provide informed consent; MASLD group:; Hepatic steatosis on MRI; BMI of 25-50 kg/m2; Controls:; Absence of hepatic steatosis on MRI; BMI of 18.5-24.9 kg/m2; No chronic disease; No long-term medications.
Exclusion: Drugs that may induce hepatic steatosis, such as methotrexate, amiodarone, tamoxifen, or Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone); Previous bariatric surgery; Type 1 Diabetes Mellitus; Chronic liver disorders (except MASLD) such as Hepatitis B, Hepatitis C, Wilson's disease, hemochromatosis, autoimmune hepatitis, chronic cholestatic disorders, and liver cirrhosis; Uncontrolled thyroid disease; Metallic implants (including incompatible pacemakers, AICD, metallic heart valves) or other contraindications to MRI; Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other, or family members); Uncontrolled diabetes (HbA1c > 8%); Clinically significant anemia (Haemoglobin < 10 g/dL); Glomerular filtration rate (GFR < 30 ml/min); Serum alanine transaminase (ALT) > 3x upper limit of normal (ULN); Serum aspartate transaminase (AST) > 3x ULN; Liver cirrhosis; Significant alcohol consumption (> 20g/day for women and >30g/day for men); Pregnancy; Weight loss > 5% in the past 1 month; Claustrophobia.